PortfoliosLab logo
BrainsWay Ltd. (BWAY)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US10501L1061

CUSIP

10501L106

IPO Date

Oct 6, 1999

Highlights

Market Cap

$202.65M

EPS (TTM)

$0.22

PE Ratio

48.64

Total Revenue (TTM)

$43.34M

Gross Profit (TTM)

$32.28M

EBITDA (TTM)

$4.90M

Year Range

$5.67 - $11.79

Target Price

$15.05

Short %

0.83%

Short Ratio

2.95

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


BrainsWay Ltd.

Popular comparisons:
BWAY vs. OB BWAY vs. BSX
Popular comparisons:

Performance

Performance Chart


Loading data...

S&P 500

Returns By Period

BrainsWay Ltd. (BWAY) returned 10.60% year-to-date (YTD) and 84.60% over the past 12 months.


BWAY

YTD

10.60%

1M

17.32%

6M

7.75%

1Y

84.60%

3Y*

13.68%

5Y*

5.98%

10Y*

N/A

^GSPC (Benchmark)

YTD

0.52%

1M

6.32%

6M

-1.44%

1Y

12.25%

3Y*

12.45%

5Y*

14.20%

10Y*

10.84%

*Annualized

Monthly Returns

The table below presents the monthly returns of BWAY, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202511.45%-9.13%-0.84%-8.45%20.30%10.60%
2024-3.40%3.51%-18.36%-0.76%19.81%-3.50%19.28%9.25%16.81%8.23%-1.30%-4.46%45.52%
2023-18.62%-3.48%-9.54%-11.68%13.23%29.91%6.58%41.98%17.10%-11.63%75.63%3.35%162.35%
20220.65%0.32%12.28%-12.14%-6.78%-32.45%27.33%-30.98%-14.96%-2.77%-46.01%30.34%-67.92%
20215.44%7.55%5.61%-4.54%29.23%-8.44%-12.16%-11.38%1.51%1.49%-5.01%-0.90%2.12%
202015.38%-5.87%-25.02%7.68%-8.77%-24.10%0.54%31.89%-25.71%-4.17%15.76%16.54%-22.67%
2019-1.98%-5.52%2.12%-5.75%1.87%-9.53%-2.31%3.71%5.63%-12.08%
Go deeper with the Portfolio Analysis tool — backtest performance, assess risk, compare to benchmarks, and more

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

With an overall rank of 90, BWAY is among the top 10% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of BWAY is 9090
Overall Rank
The Sharpe Ratio Rank of BWAY is 9191
Sharpe Ratio Rank
The Sortino Ratio Rank of BWAY is 9191
Sortino Ratio Rank
The Omega Ratio Rank of BWAY is 8686
Omega Ratio Rank
The Calmar Ratio Rank of BWAY is 9090
Calmar Ratio Rank
The Martin Ratio Rank of BWAY is 9191
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for BrainsWay Ltd. (BWAY) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

BrainsWay Ltd. Sharpe ratios as of May 30, 2025 (values are recalculated daily):

  • 1-Year: 1.58
  • 5-Year: 0.10
  • All Time: -0.02

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of BrainsWay Ltd. compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.


Loading data...

Go to the full Sharpe Ratio tool to analyze any stock or portfolio. Customize time frames, set your own risk-free rate, and more

Dividends

Dividend History


BrainsWay Ltd. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the BrainsWay Ltd.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the BrainsWay Ltd. was 88.14%, occurring on May 10, 2023. The portfolio has not yet recovered.

The current BrainsWay Ltd. drawdown is 15.27%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-88.14%Jan 23, 2020831May 10, 2023
-27.83%Apr 23, 2019147Nov 18, 201940Jan 16, 2020187
-0.09%Jan 17, 20201Jan 17, 20201Jan 21, 20202
Go to the full Drawdowns tool for more analysis options, including inflation-adjusted drawdowns, and more

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of BrainsWay Ltd. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of BrainsWay Ltd., comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -14.2%.


-0.30-0.25-0.20-0.15-0.10-0.050.000.0520212022202320242025
0.02
0.02
Actual
Estimate

Valuation

The Valuation section provides an overview of how BrainsWay Ltd. is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio

The chart displays the Price-to-Earnings (P/E) ratio for BWAY, comparing it with other companies in the Medical Devices industry. Currently, BWAY has a P/E ratio of 48.6. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for BWAY relative to other companies in the Medical Devices industry. Currently, BWAY has a P/S ratio of 4.7. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for BWAY in comparison with other companies in the Medical Devices industry. Currently, BWAY has a P/B value of 3.2. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items